• Email Alerts
  • Careers
  • Contact Us

SCYNEXIS, Inc.

  • Home
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
    • Careers
    • Contact
  • Pipeline
    • Ibrexafungerp Development Pipeline
    • Clinical Trials
    • Vulvovaginal Candidiasis
    • Invasive Candidiasis
    • Invasive Aspergillosis
    • Refractory Invasive Fungal Infections
  • Science
    • SCYNEXIS Research Platform
    • Publications and Presentations
    • Expanded Access
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Data

Publications

Science

Science

  • SCYNEXIS Research Platform
  • Publications and Presentations
    • Publications
    • Posters and Presentations
  • Expanded Access
  • Publications and Presentations

  • Publications
  • Posters and Presentations

Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus

Wring S, Murphy G, Atiee G, Corr C, Hyman M, Willett M, Angulo D.
Clinical Pharmacology in Drug Development
June 2018

Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions

Wring S, Murphy G, Atiee G, Corr C, Hyman M, Willett M, Angulo D.
Journal of Clinical Pharmacology
May 2018

Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species

Schell WA, Jones AM, Borroto-Esoda K, Alexander B
Antimicrobial Agents and Chemotherapy
November 2017

De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations that both Overlap and are Distinct from those Conferring Echinocandin Resistance

Jimenez-Ortigosa C, Perez WB, Angulo D, Borroto-Esoda K, Perlin DS
Antimicrobial Agents and Chemotherapy
September 2017

Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-resistant Strains of Candida Species

Pfaller MA, Messer SA, Rhomberg PR, Borroto-Esoda K, Castanheira M
Antimicrobial Agents and Chemotherapy
August 2017

In vitro Activity of Novel Glucan Synthase Inhibitor SCY-078 against Clinical Isolates of Candida auris

Berkow EL, Angulo D, Lockhart SR
Antimicrobial Agents and Chemotherapy
July 2017

The Novel Oral Glucan Synthase Inhibitor SCY-078 shows In vitro Activity against Sessile and Planktonic Candida spp

Marcos-Zambrano LJ, Gomez-Perosanz M, Escribano P, Bouza E, Guinea
Journal of Antimicrobial Chemotherapy
July 2017

Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.

S. Wring, R. Randolph, S. Park, G. Abruzzo, Q. Chen, A. Flattery, G. Garrett, M. Peel, R. Outcalt, K. Powell, M. Trucksis, D. Angulo, K. Borroto-Esoda
Antimicrobial Agents and Chemotherapy
March 2017

The Emerging Candida auris: Characterization of Growth Phenotype, Virulence Factors, Antifungal Activity, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation.

E. Larkin, C. Hager, J. Chandra, P. Mukherjee, M. Retuerto, I. Salem, L. Long, N. Isham, L. Kovanda, K. Borroto-Esoda, S. Wring, D. Angulo, M. Ghannoum
Antimicrobial Agents and Chemotherapy
February 2017

SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies.

B. Scorneaux, D. Angulo, K. Borroto-Esoda, M. Ghannoum, M. Peel, S. Wring
Antimicrobial Agents and Chemotherapy
February 2017

1 Evertrust Plaza, Jersey City, NJ 07302
(201) 884-5485
View Google Map

© 2019 SCYNEXIS, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Contact Us